Copper-64 trastuzumab PET imaging: A reproducibility study Journal Article


Authors: Carrasquillo, J. A.; Morris, P. G.; Humm, J. L.; Smith-Jones, P. M.; Beylergil, V.; Akhurst, T.; O'Donoghue, J. A.; Ruan, S.; Modi, S.; Hudis, C. A.; Larson, S. M.
Article Title: Copper-64 trastuzumab PET imaging: A reproducibility study
Abstract: BACKGROUND: The current study aims to assess the safety, pharmacokinetics, feasibility, and reproducibility of immunoPET imaging with copper-64 (64Cu) trastuzumab. METHODS: An IV injection of 296-370 MBq/5 mg 64Cu-trastuzumab was administered between 1 to 4 hours after routine trastuzumab treatment. Whole-body PET scans were performed immediately post-injection and at 24 hours post-injection. Serial pharmacokinetics were performed. Of 11 patients (median age of 52; range of 31-61), 8 underwent a repeat study with 64Cu-trastuzumab to assess image and pharmacokinetic reproducibility. Patients were monitored for toxicity. RESULTS: Patients experienced no allergic reactions or significant adverse effects from 64Cu-trastuzumab. Eight patients successfully completed a repeat 64Cu-trastuzumab study, with acceptable reproducibility of both the biodistribution and pharmacokinetic clearance. Study 1 versus study 2 showed similar serum concentration post-injection (mean 42.4±7.8 %ID/L vs. 44.7±12.6 %ID/L) and similar T1/2 (single exponential 46.1 vs. 44.2 hours), P>0.5. The volume of distribution (median 2.50 L) was in the range reported for trastuzumab and close to the estimated plasma volume of 2.60 L. Of 11 patients, two had 64Cu-trastuzumab localization corresponding to known tumor sites - one in liver and one in breast. CONCLUSIONS: Preliminary results suggest that scanning with 64Cu-trastuzumab is feasible, safe, and reproducible. Tumor uptake of 64Cu-trastuzumab was observed, but tumor detection exhibited low sensitivity in this study in which imaging was performed in the presence of trastuzumab therapy.
Journal Title: Quarterly Journal of Nuclear Medicine and Molecular Imaging
Volume: 63
Issue: 2
ISSN: 1824-4785
Publisher: Edizioni Minerva Medica  
Date Published: 2019-06-01
Start Page: 191
End Page: 198
Language: English
DOI: 10.23736/s1824-4785.16.02867-3
PUBMED: 27171605
PROVIDER: scopus
PMCID: PMC9185799
DOI/URL:
Notes: Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Patrick Glyn Morris
    116 Morris
  2. Clifford Hudis
    905 Hudis
  3. Shanu Modi
    265 Modi
  4. Timothy J Akhurst
    139 Akhurst
  5. John Laurence Humm
    433 Humm
  6. Shutian Ruan
    56 Ruan
  7. Steven M Larson
    958 Larson